Detalhe da pesquisa
1.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
N Engl J Med
; 388(15): 1353-1364, 2023 Apr 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36876740
2.
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Circulation
; 149(1): 28-35, 2024 01 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37929602
3.
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
JAMA
; 330(2): 131-140, 2023 07 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37354546
4.
Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex.
Circulation
; 2024 Apr 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38581406
5.
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Circulation
; 140(19): 1578-1589, 2019 11 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31475572
6.
Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry.
Am Heart J
; 225: 88-96, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32485329
7.
Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry.
Am Heart J
; 214: 113-124, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31202098
8.
Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndromeã- The ODYSSEY J-IVUS Trial.
Circ J
; 83(10): 2025-2033, 2019 09 25.
Artigo
Inglês
| MEDLINE | ID: mdl-31434809
9.
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Kidney Int
; 93(6): 1397-1408, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29526502
10.
Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry.
Am Heart J
; 200: 118-124, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29898839
11.
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Diabetes Obes Metab
; 20(7): 1632-1641, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29493859
12.
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 181, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29713852
13.
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 175-180, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29627892
14.
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Diabetes Obes Metab
; 19(7): 989-996, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28206704
15.
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Lancet Diabetes Endocrinol
; 12(1): 19-28, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38061370
16.
Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
J Clin Lipidol
; 18(1): e59-e69, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-37951797
17.
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
Atherosclerosis
; 378: 117182, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37517922
18.
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
Am J Cardiovasc Drugs
; 23(1): 67-76, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36316612
19.
Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation.
Pharmaceutics
; 15(5)2023 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37242718
20.
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
J Am Heart Assoc
; 11(15): e024531, 2022 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35916348